| Assay ID | Title | Year | Journal | Article |
|---|
| AID227092 | Ratio of the IC50 of Kappa receptor agonist, ethylketazocine in the presence of compound in GPI divided by the control IC50. | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID148972 | Opioid antagonist potencies against Opioid receptor kappa 1 from guinea pig ileum employing ethylketazocine (EKC) as agonist. | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID148589 | Effect on binding to kappa(Glu297Ala) opioid receptor, using [3H]diprenorphine in transiently expressed rat HEK293 cells | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID148575 | Binding affinity towards rat opioid receptor kappa 1 was determined using [3H]diprenorphine radioligand | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID152389 | Displacement of [3H]- diprenorphine from mu-receptor expressed in HEK 293 cells | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
| Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. |
| AID381429 | Increase of JNK phosphorylation in U50488 treated untransfected HEK293 cells at 10 uM after 1 hr | 2007 | The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
| Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. |
| AID149783 | Inhibition of [3H]-DADLE binding to Opioid receptor delta 1 of rat brain tissue | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. |
| AID148704 | Opioid antagonist potency, determined in the guinea pig ileum (GPI) preparation, by employing EK (kappa-opioid) as agonist, expressed as IC50 ratio (tested at 20 nM) | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID148588 | Effect on binding affinity of mutational exchange of Glu297 in the Opioid receptor kappa 1 in transiently expressed rat cos-7 cells activity expressed as binding affinity. | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID149260 | Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of guinea pig brain | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. |
| AID603175 | Displacement of [125I]-IBNalA from KOR-1 expressed in CHO cells | 2011 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
| Generation of novel radiolabeled opiates through site-selective iodination. |
| AID148975 | Opioid receptor kappa 1 Antagonism (100 nM) is expressed as (Ke = [antagonist] / (IC50 ratio -1) | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID152386 | Displacement of [3H]- diprenorphine from mu-K303E-receptor expressed in HEK 293 cells | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
| Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. |
| AID229883 | Selectivity ratio, ratio of binding affinity of mu to kappa opioid receptor | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID227093 | Ratio of the IC50 of delta receptor agonist, [D-Ala-2, D-Leu5]-enkephalin in the presence of compound in MVD divided by the control IC50. | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID756068 | Selectivity ratio of Ki for delta opioid receptor (unknown origin) to Ki for kappa opioid receptor (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives. |
| AID756071 | Selectivity ratio of Ki for mu opioid receptor (unknown origin) to Ki for kappa opioid receptor (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives. |
| AID148447 | Mutant factor against mutant receptor with Opioid receptor kappa 1 | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID149675 | Binding affinity on HEK293 cells transiently transfected with plasmids encoding the rat Opioid receptor delta 1 | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID147887 | Opioid antagonist potencies against Opioid receptor mu 1 from guinea pig ileum employing morphine(M) as agonist. | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID147889 | Opioid receptor mu 1 Antagonism (100 nM) is expressed as (Ke = [antagonist] / (IC50 ratio -1) | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID152388 | Displacement of [3H]- diprenorphine from mu-W318A-receptor expressed in HEK 293 cells | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
| Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. |
| AID148973 | Opioid antagonist potency towards opioid receptor kappa 1 determined in guinea pig ileum preparation | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID151766 | Effect on binding affinity of mutational exchange of Lys303 in the Opioid receptor mu 1 in transiently expressed rat cos-7 cells activity expressed as binding affinity. | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID149086 | Displacement of [3H]- diprenorphine from delta-W284E-receptor expressed in HEK 293 cells | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
| Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. |
| AID148446 | Effect on binding affinity of mutational exchange of Glu297 in the Opioid receptor kappa 1 in transiently expressed rat cos-7 cells activity expressed as binding ratio with nor-BNI. | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID152373 | Binding affinity towards rat mu-opioid receptor was determined using [3H]diprenorphine as radioligand | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID233597 | Ratio of Ke value to kappa receptor to that of mu receptor | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID148598 | Mutant factor of the compound against kappa[E297K] with Opioid receptor kappa 1 for binding affinity. | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID148786 | Opioid antagonist potency, determined in mouse vas deferens (MVD) preparation, using DADLE (delta-opioid) as agonist, expressed as IC50 ratio | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID229881 | Selectivity ratio, ratio of Ke value of mu to kappa opioid receptor | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID229882 | Selectivity ratio, ratio of binding affinity of delta to kappa opioid receptor | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID151620 | Inhibition of [3H]DAMGO binding to Opioid receptor mu 1 of rat brain tissue | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. |
| AID148590 | Effect on binding to wild-type opioid receptor kappa 1 using [3H]diprenorphine in transiently expressed rat HEK293 cells | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID229876 | Selectivity ratio, ratio of Ke value of Kappa to Delta opioid receptor (extrapolated value) | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID152219 | Opioid antagonist potency, determined in guinea pig ileum (GPI) preparation, using morphine (mu-opioid) as agonist, expressed as IC50 ratio | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID233596 | Ratio of Ke value to kappa receptor to that of delta receptor | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID415716 | Selectivity ratio of Ki for delta opioid receptor to Ki for kappa opioid receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies. |
| AID148169 | Antagonistic activity against human cloned kOpioid receptor kappa 1 using U69,593 in [35S]GTP-gamma-S, assay | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. |
| AID603174 | Displacement of [125I]-IBNtxA from KOR-1 expressed in CHO cells | 2011 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
| Generation of novel radiolabeled opiates through site-selective iodination. |
| AID148585 | Displacement of [3H]diprenorphine from k-Y312A-receptor expressed in HEK 293 cells | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
| Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. |
| AID149248 | Binding affinity towards mouse delta-opioid receptor was determined using [3H]diprenorphine as radioligand | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID148939 | Opioid antagonist potency, determined in mouse vas deferens (MVD) preparation, using DADLE (delta-opioid) as agonist (Ke=antagonist/IC50 ratio -1) | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID233363 | Selectivity ratio of mu and kappa opioid receptor | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. |
| AID152223 | Opioid antagonist potency, determined in guinea pig ileum (GPI) preparation, using morphine (mu-opioid) as agonist (Ke=antagonist/IC50 ratio -1) | 2001 | Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
| Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. |
| AID779513 | Selectivity ratio of Ki for DOR (unknown origin) to Ki for KOR (unknown origin) | 2013 | Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
| Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opio |
| AID148383 | Antagonistic activity against human cloned Opioid receptor delta 1 using DPDPE in [35S]GTP-gamma-S, assay | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. |
| AID149085 | Displacement of [3H]- diprenorphine from delta receptor expressed in HEK 293 cells | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
| Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. |
| AID148568 | Binding affinity on HEK293 cells transiently transfected with plasmids encoding the rat Opioid receptor kappa 1 | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID151116 | Antagonistic activity against human cloned Opioid receptor mu 1 using DPDPE in [35S]GTP-gamma-S, assay | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. |
| AID381420 | Inhibition of U50488-induced analgesic activity against C57BL/6 mouse assessed as tail withdrawal latency at 10 mg/kg, ip upto 21 days | 2007 | The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
| Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. |
| AID148584 | Displacement of [3H]diprenorphine from k-E297A-receptor expressed in HEK 293 cells | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
| Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. |
| AID148938 | Opioid antagonist potencies against Opioid receptor delta 1 from mouse vas-deferens preparation employing [D-Ala2,D-Leu5]enkephalin (DADLE) as agonist. | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID415715 | Selectivity ratio of Ki for mu opioid receptor to Ki for kappa opioid receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies. |
| AID148599 | Mutant factor of the compound against mu-[K303E] with Opioid receptor kappa 1 for binding affinity | 1998 | Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
| Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. |
| AID148586 | Displacement of [3H]diprenorphine from opioid receptor kappa 1 expressed in HEK 293 cells | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
| Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. |
| AID227211 | Ratio of the IC50 of mu receptor agonist, Morphine in the presence of compound in GPI divided by the control IC50. | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID779514 | Selectivity ratio of Ki for MOR (unknown origin) to Ki for KOR (unknown origin) | 2013 | Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
| Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opio |
| AID233141 | Selectivity ratio of delta and kappa opioid receptor | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. |
| AID151614 | Binding affinity on HEK293 cells transiently transfected with plasmids encoding the rat Opioid receptor mu 1 | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID148942 | Opioid receptor delta 1 Antagonism (100 nM) is expressed as (Ke = [antagonist] / (IC50 ratio -1) | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
| A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500
| Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | | | |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | | | |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500
| Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500
| Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1346329 | Human kappa receptor (Opioid receptors) | 2000 | European journal of pharmacology, May-12, Volume: 396, Issue:1
| 5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. |
| AID1346329 | Human kappa receptor (Opioid receptors) | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
| Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |